Nkarta, Inc.
Financials
Valuation Metrics
Nkarta, Inc.'s Market Cap is $108M. At end of 2025 it was $137M. Ranked #3048 of 3,114 in US market (top 98%), #1411 of 1,469 on NASDAQ (top 96%), #257 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 97%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $108M | US#3,048/3,114 Sec#257/265 |
| Revenue | $0.00 | US#2,862/3,114 Sec#194/265 |
| Net Income | $-117M | US—/3,114 Sec—/265 |
| Total Assets | $338M | US#2,881/3,114 Sec#199/265 |
| Net Assets | $248M | US#2,589/3,114 Sec#168/265 |
| Employees | 106 | US#2,603/3,114 Sec#172/265 |
| Value | ||
| P/B | 0.44x | US#94/3,114 Sec#5/265 |
| FCF Yield | -86.63% | US—/3,114 Sec—/265 |
| Profitability | ||
| ROE | -47.36% | US#2,665/3,114 Sec#154/265 |
| ROA | -34.75% | US#2,918/3,114 Sec#175/265 |
| Financial Health | ||
| Debt Ratio | 36.29% | US#414/3,114 Sec#119/265 |
| Total Debt | $74M | US#2,520/3,114 Sec#136/265 |
| FCF | $-94M | US#2,629/3,114 Sec#141/265 |
| Cash | $25M | US#2,806/3,114 Sec#249/265 |
| Current Ratio | 7.98x | US#317/3,114 Sec#98/265 |
| Performance | ||
| 1Y Return | -28.20% | US#2,399/3,114 Sec#190/265 |
| 1M Return | -41.28% | US#3,043/3,114 Sec#258/265 |
| From 52W High | -59.27% | US#2,699/3,114 Sec#210/265 |
| 1Y MDD | -58.72% | US#2,492/3,114 Sec#176/265 |
| Trading | ||
| Volume | 1,283,819 shares | US#1,120/3,114 Sec#93/265 |
| Trading Value | $2M | US#2,800/3,114 Sec#231/265 |
| Per Share | ||
| EPS | $-1.64 | US—/3,114 Sec—/265 |
| BPS | $3.46 | US#2,420/3,114 Sec#154/265 |
Company Info
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.